Payment overview · 2025
General Payments
$2,615.26
20 reported records · 9 companies
Healthcare provider profile · identity verified
Birjitender Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAGINAW, MI · NPI 1124131719
Verified facts
What the public records show
CMS Open Payments records show Birjitender Singh, MD received $2,615.26 in general payments during 2025 across 20 reported records.
MIMEDX Group, Inc. accounted for 88.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $2,305.70 | 88.2% | 9 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $103.95 | 4.0% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $56.09 | 2.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.01 | 1.4% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $33.77 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.30 | 1.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.72 | 0.8% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $17.12 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.60 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,759.75 | 4 |
| Food and Beverage | $751.56 | 15 |
| Education | $103.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $103.95 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $56.09 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 766 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 77 |
| Losartan Potassium | Losartan Potassium | 190 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 49 |
| Lisinopril | Lisinopril | 164 | 45 |
| Omeprazole | Omeprazole | 158 | 40 |
| Potassium Chloride | Potassium Chloride | 146 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 36 |
| Metformin Hcl | Metformin Hcl | 132 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 96 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 27 |
| Allopurinol | Allopurinol | 87 | 27 |
| Jardiance | Empagliflozin | 87 | 23 |
| Alprazolam | Alprazolam | 79 | 12 |
| Simvastatin | Simvastatin | 77 | 20 |
| Furosemide | Furosemide | 75 | 27 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 74 | suppressed |
| Gabapentin | Gabapentin | 74 | 19 |
| Sertraline Hcl | Sertraline Hcl | 69 | 16 |
| Tramadol Hcl | Tramadol Hcl | 64 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 20 |
| Lorazepam | Lorazepam | 59 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 16 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Ozempic | Semaglutide | 52 | 12 |
| Eliquis | Apixaban | 50 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 15 |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Glipizide | Glipizide | 45 | 11 |
| Diazepam | Diazepam | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Carvedilol | Carvedilol | 40 | 11 |
| Famotidine | Famotidine | 40 | 15 |
| Celecoxib | Celecoxib | 38 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | 11 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 32 | 27 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,615.26 · 20 records | MIMEDX Group, Inc. | AIRSUPRA, Cologuard Collection Kit, DUROLANE, Ozempic, Rybelsus, SUBLOCADE, VIVITROL, VRAYLAR, Zubsolv | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error